CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 23,003		$ 27,793	$ 1,935
Operating expenses:
Cost of goods sold			2,081
Research and development	19,905	$ 25,225	41,178	44,356
General and administrative	7,570	5,651	16,917	12,016
Total operating expenses	27,475	30,876	60,176	56,372
Operating loss	(4,472)	(30,876)	(32,383)	(54,437)
Other income, net	266	131	428	391
Net loss	$ (4,206)	$ (30,745)	$ (31,955)	$ (54,046)
Net loss per share:
Basic	$ (0.08)	$ (0.61)	$ (0.60)	$ (1.08)
Diluted	$ (0.08)	$ (0.61)	$ (0.60)	$ (1.08)
Weighted average shares:
Basic	53,614,668	50,059,984	53,561,161	49,989,379
Diluted	53,614,668	50,059,984	53,561,161	49,989,379
Other comprehensive loss, net of tax of $0:
Change in unrealized losses on available-for-sale marketable securities	$ (324)	$ (17)	$ (1,689)	$ (78)
Total comprehensive loss	(4,530)	$ (30,762)	(33,644)	(54,124)
License and Milestone Fees
Revenue:
Total revenue	15,000		15,000	1,192
Collaborative Revenue
Revenue:
Total revenue	$ 8,003		8,003	706
Commercial Supply Revenue
Revenue:
Total revenue			$ 4,790
Clinical Compound Revenue
Revenue:
Total revenue				$ 37